Mobilizing the Supercharged Immune Armies Within
AVM Biotechnology - Providing Advanced Solutions to Complex Disease
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T-like immune cells. These TCR bispecific immune cells have unique immune response properties in comparison to ordinary T-cells and rapidly appear following a single AVM0703 dose. Pre-clinical and clinical data indicate that these cells could play a significant role in several diseases and conditions.